NYSEInformation TechnologyInformation Technology ServicesSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Oct 4, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for CSQR yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
improvement in operational efficiency | The company is also focused on improving operational efficiency. | Intact | no significant operational improvements reported | Qualitative condition This condition has no defined numerical measure. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · alphavantage
$-1.02 → $-1.02 · observed estimates
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 9, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
CSQR looks like a growth-sensitive Tech exposure, but the evidence is too thin to label it a durable compounder or a turnaround. The current long-term thesis is insufficiently established, despite stable management and a recent reduction in measured risk.
The snapshot provides no valuation level or evidence about market expectations, so whether CSQR is cheap, fair, or expensive versus peers cannot be assessed. It reports low fragility, meaning the listed conditions did not flag concentrated risk, but this does not show what the market already assumes.
Near term, the direction of CSQR’s fundamentals is unclear: an August earnings release is noted, but no results or guidance are provided. Total stock risk and market risk both fell from 44.5 to 30.6, while the divestiture is listed without details; neither establishes a business trend.
A favorable near-term setup would depend on Fed rate cuts from 3.88% or signs that Tech bellwethers IBM, ACN, and CTSH are stabilizing. A material slowdown in GDP from 2.1% to below 2% is a stated risk for growth-sensitive Tech names. The multi-year view also needs clearer evidence on CSQR’s financial performance and the effects of its divestiture.
Over the next 1 to 3 years, CSQR’s thesis is unresolved: risk measures have eased, but the evidence does not establish valuation or fundamental momentum. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| Profit margins are expected to stabilize around 15%. |
| Under Pressure |
| falls below 12% next year |
Net margin: -17.42% FY2026-Q2; GAAP. Published target: >=15%. Target period is not explicitly aligned with this observation. Aug 10, 2026-17.416382 percent · calculatedLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
annual revenue growth of about 10% | A primary condition in CSQUARE INC's published investment case. The stated target is >=10% YoY. | Intact | falls below 5% YoY growth next year | Required source inputs unavailable Cannot calculate Revenue growth from the available matching source inputs. Missing inputs are not treated as zero. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Oct 4, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$1.32B → $1.32B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-10-25 | $-1.02 | $1,324,378,940 | 7 / 9 |
| 2026-10-26 | $-1.02 | $1,324,378,940 | 7 / 9 |
| 2026-10-27 | $-1.02 | $1,324,378,940 | 7 / 9 |
| 2026-10-28 | $-1.02 | $1,324,378,940 | 7 / 9 |
| 2026-10-29 | $-1.02 | $1,324,378,940 | 7 / 9 |
| 2026-10-30 | $-1.02 | $1,324,378,940 | 7 / 9 |
| 2026-10-31 | $-1.02 | $1,324,378,940 | 7 / 9 |
| 2026-11-01 | $-1.02 | $1,324,378,940 | 7 / 9 |
| 2026-11-02 | $-1.02 | $1,324,378,940 | 7 / 9 |
| 2026-11-03 | $-1.02 | $1,324,378,940 | 7 / 9 |
| 2026-11-04 | $-1.02 | $1,324,378,940 | 7 / 9 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 9 Buy / Strong Buy · 1 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.